Triple therapy for H. pylori refers to a proton pump inhibitor, also known as a PPI, plus two antibiotics. At present, triple therapy is relatively less used in the domestic expert consensus, because the eradication rate of triple drugs is found to be declining in China. Therefore, quadruple therapy is now advocated, that is, adding a bismuth preparation to the triple combination, which can improve the eradication rate of H. pylori. And in foreign countries may be more with the triple therapy, because foreign countries to implement the meal system, may antibiotic resistance rate is relatively low. So it has been advocated that we must start from the source of animal husbandry and farming to minimize the application of antibiotics in these two segments. Also advocate that patients should not easily use antibiotics, such as the common cold to infusion using antibiotics is not desirable. In addition, it is important to promote the meal sharing system, which can reduce cross-infection in order to improve the eradication rate of H. pylori and reduce the recurrence rate and reinfection rate. Therefore, the initial H. pylori eradication treatment usually uses quadruple therapy, in the process of quadruple therapy, which antibiotics and which PPI drugs are chosen may be integrated according to the state of the patient and whether there is a history of drug allergy.